Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Assertio Therapeutics (ASRT – Research Report) and keeping the price target at $3.50.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Ram Selvaraju has given his Buy rating due to a combination of factors, including the reaffirmation of Assertio Therapeutics’ revenue guidance despite a recent miss in top- and bottom-line expectations. The company has maintained its revenue guidance range for 2025, and Selvaraju anticipates that Assertio will narrow this range as the year progresses, reflecting confidence in its financial outlook. Additionally, the long-term growth potential of ROLVEDON, a key product, remains strong, with sales exceeding internal expectations and expected to continue growing sequentially.
Despite a net loss reported in the first quarter of 2025, Selvaraju projects Assertio to return to profitability in the second half of 2026. The gross margins have shown improvement, and there is potential for further enhancement as ROLVEDON becomes a larger portion of total sales. Furthermore, the company’s intention to introduce another branded product to the U.S. market could positively impact gross margins. These factors collectively support Selvaraju’s Buy rating and the 12-month price target of $3.50.
Selvaraju covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Niagen Bioscience, and Emergent Biosolutions. According to TipRanks, Selvaraju has an average return of 7.7% and a 37.70% success rate on recommended stocks.
In another report released on May 14, Maxim Group also reiterated a Buy rating on the stock with a $3.00 price target.
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue